for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

セルジーン・コーポレーション

CELG.O

前日終値

109.32USD

変化

--(--)

本日のレンジ

--

 - 

--

52週レンジ

58.59

 - 

110.70

∙ 約15分前の相場を表示しています。

適時開示

Bristol-Myers Squibb Co Says It Expects No Further Extension Of Expiration Date For Exchange Offers For Celgene Corp Notes

Nov 15 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::MPANY ANNOUNCES IT EXPECTS NO FURTHER EXTENSION OF THE EXPIRATION DATE FOR EXCHANGE OFFERS FOR CELGENE CORPORATION NOTES.BRISTOL-MYERS-SEES NO FURTHER EXTENSION OF EXPIRATION DATE OF EXCHANGE OFFERS CELGENE NOTES UP TO $19.85 BILLION PRINCIPAL AMOUNT OF NEW NOTES TO BE ISSUED BY CO.CLOSING OF MERGER IS EXPECTED TO OCCUR ON NOVEMBER 20, 2019.BRISTOL-MYERS- CURRENTLY EXPECTS THERE WILL BE NO FURTHER EXTENSION OF EXPIRATION DATE; IT IS ANTICIPATED MERGER WILL BE COMPLETED ON EXPIRATION DATE.SETTLEMENT DATE FOR EXCHANGE OFFERS IS EXPECTED TO OCCUR ON NOVEMBER 22, 2019.

Celgene Receives CHMP Positive Opinion For Revlimid

Nov 15 (Reuters) - Celgene Corp <CELG.O>::CELGENE RECEIVES CHMP POSITIVE OPINION FOR REVLIMID® (LENALIDOMIDE) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA.CELGENE CORP - POSITIVE OPINION WAS BASED ON RESULTS OF PHASE 3 AUGMENT STUDY.

Skyhawk Therapeutics Announces Second Collaboration Agreement With Celgene

Nov 12 (Reuters) - Skyhawk Therapeutics: :SKYHAWK THERAPEUTICS ANNOUNCES A SECOND MULTI-TARGET COLLABORATION AGREEMENT WITH CELGENE TO DISCOVER AND DEVELOP NOVEL SMALL MOLECULES THAT MODULATE RNA SPLICING.SKYHAWK THERAPEUTICS, INC - SKYHAWK TO RECEIVE $80 MILLION UPFRONT PAYMENT AND IS ELIGIBLE FOR POTENTIAL MILESTONE PAYMENTS AND ROYALTIES.SKYHAWK THERAPEUTICS, INC - ENTERED INTO SECOND GLOBAL STRATEGIC COLLABORATION WITH AFFILIATE OF CELGENE CORPORATION.

Skyhawk Therapeutics Announces Collaboration Agreement With Celgene

Nov 12 (Reuters) - Celgene Corp <CELG.O>::SKYHAWK THERAPEUTICS ANNOUNCES A SECOND MULTI-TARGET COLLABORATION AGREEMENT WITH CELGENE TO DISCOVER AND DEVELOP NOVEL SMALL MOLECULES THAT MODULATE RNA SPLICING.SKYHAWK THERAPEUTICS - TO RECEIVE $80 MILLION UPFRONT PAYMENT AND IS ELIGIBLE FOR POTENTIAL MILESTONE PAYMENTS AND ROYALTIES.SKYHAWK THERAPEUTICS - CELGENE TO RECEIVE EXCLUSIVE OPTIONS TO LICENSE A NUMBER OF SKYHAWK'S PRODUCT CANDIDATES.

Acceleron Pharma Says FDA Approves Reblozyl For Treatment Of Anemia In Adults With Beta Thalassemia Who Need Regular RBC Transfusions

Nov 8 (Reuters) - Acceleron Pharma Inc <XLRN.O>::FDA APPROVES REBLOZYL® (LUSPATERCEPT-AAMT) FOR THE TREATMENT OF ANEMIA IN ADULTS WITH BETA THALASSEMIA WHO REQUIRE REGULAR RED BLOOD CELL TRANSFUSIONS.ACCELERON PHARMA INC - REBLOZYL IS ANTICIPATED TO BE AVAILABLE 1 WEEK FOLLOWING FDA APPROVAL.

FDA Approves Celgene's Rare Blood Disorder Drug

Nov 8 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES FIRST THERAPY TO TREAT PATIENTS WITH RARE BLOOD DISORDER.FDA - GRANTED APPROVAL TO REBLOZYL FOR TREATMENT OF ANEMIA IN ADULT PATIENTS WITH BETA THALASSEMIA WHO REQUIRE REGULAR RED BLOOD CELL TRANSFUSIONS.FDA - GRANTED APPROVAL OF REBLOZYL TO CELEGENE CORPORATION.

Bristol-Myers Squibb Qtrly GAAP EPS $0.83

Oct 31 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL-MYERS SQUIBB - QTRLY GAAP EPS OF $0.83 AND NON-GAAP EPS OF $1.17.BRISTOL-MYERS SQUIBB - DECREASING 2019 GAAP EPS GUIDANCE RANGE FROM $3.73 - $3.83 TO $3.46 - $3.56.BRISTOL-MYERS SQUIBB - QTRLY TOTAL REVENUE $6,007 MILLION VERSUS $5,691 MILLION.BRISTOL-MYERS SQUIBB - INCREASING 2019 NON-GAAP EPS GUIDANCE RANGE FROM $4.20 - $4.30 TO $4.25 - $4.35.BRISTOL-MYERS SQUIBB - FY GUIDANCE EXCLUDES IMPACT OF FUTURE DEALS, INCLUDING IMPACT OF PENDING CELGENE DEAL OTHER THAN EXPENSES INCURRED IN 2019.BRISTOL-MYERS SQUIBB - QTRLY WORLDWIDE OPDIVO REVENUE $1,817 MILLION VERSUS $1,793 MILLION.BRISTOL-MYERS SQUIBB - QTRLY WORLDWIDE ELIQUIS REVENUE $1,928 MILLION VERSUS $1,577 MILLION.FY2019 EARNINGS PER SHARE VIEW $4.28 -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE VIEW $1.07, REVENUE VIEW $5.89 BILLION -- REFINITIV IBES DATA.

Phathom Pharmaceuticals Says Terrie Curran To Succeed David Socks As CEO

Sept 27 (Reuters) - Celgene Corp <CELG.O>::PHATHOM PHARMACEUTICALS ANNOUNCES LEADERSHIP SUCCESSION PLAN AND STRENGTHENS BOARD OF DIRECTORS WITH NEW APPOINTMENTS.PHATHOM PHARMACEUTICALS - TERRIE CURRAN, PRESIDENT, GLOBAL INFLAMMATION AND IMMUNOLOGY FRANCHISE AT CELGENE CORP, TO SUCCEED DAVID SOCKS AS CEO.PHATHOM PHARMACEUTICALS - SOCKS TO CONTINUE TO SERVE AS CEO UNTIL CURRAN JOINS & THEN SERVE AS INTERIM CFO, CONTINUE TO SERVE AS MEMBER OF BOARD.PHATHOM PHARMACEUTICALS - MICHAEL COLA, TERRIE CURRAN, HEIDI KUNZ, AND CHRIS SLAVINSKY APPOINTED TO BOARD OF DIRECTORS.

Celgene's Cc-486 Tested As Maintenance Therapy For AML Succeeds In Phase 3 Study

Sept 12 (Reuters) - Celgene Corp <CELG.O>::CELGENE ANNOUNCES PHASE 3 QUAZAR® AML-001 STUDY OF CC-486 AS MAINTENANCE THERAPY IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA MET PRIMARY AND KEY SECONDARY ENDPOINTS.CELGENE CORP - TOP-LINE ANALYSIS SHOWED A HIGHLY STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OVERALL SURVIVAL FOR CC-486.CELGENE CORP - CELGENE PLANS REGULATORY SUBMISSIONS BEGINNING IN 1H 2020.CELGENE CORP - CC-486 WAS WELL-TOLERATED AND THERE WERE NO UNEXPECTED SAFETY EVENTS IN QUAZAR AML-001.CELGENE CORP - KEY SECONDARY ENDPOINT OF RELAPSE-FREE SURVIVAL (RFS) ALSO SHOWED A STATISTICALLY SIGNIFICANT IMPROVEMENT..CELGENE CORP - DATA FROM QUAZAR AML-001 WILL BE SUBMITTED TO A FUTURE MEDICAL MEETING..

U.S. FDA Approves Inrebic As First New Treatment In Nearly A Decade For Patients With Myelofibrosis

Aug 16 (Reuters) - Celgene Corp <CELG.O>::U.S. FDA APPROVES INREBIC® (FEDRATINIB) AS FIRST NEW TREATMENT IN NEARLY A DECADE FOR PATIENTS WITH MYELOFIBROSIS.CELGENE CORP - INREBIC PROVIDES NEW, ONCE-DAILY ORAL OPTION FOR PATIENTS AFFECTED BY RARE BONE MARROW CANCER.

金融情報はリフィニティブから。すべての情報は少なくとも15分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up